{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:50:29Z","timestamp":1768423829892,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","funder":[{"name":"F. Hoffman-La Roche Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s12325-016-0398-2","type":"journal-article","created":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T13:55:34Z","timestamp":1471442134000},"page":"1814-1830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8212-7459","authenticated-orcid":false,"given":"Nicolas","family":"St\u00e4dler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijing","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Goede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelien","family":"Berthier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Renaudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,17]]},"reference":[{"issue":"9747","key":"398_CR1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164\u201374.","journal-title":"Lancet"},{"issue":"suppl 5","key":"398_CR2","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","volume":"26","author":"B Eichhorst","year":"2015","unstructured":"Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v78\u201384.","journal-title":"Ann Oncol"},{"key":"398_CR3","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Non-Hodgkin\u2019s lymphoma. Version 1.2016. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site . Last accessed December, 2015."},{"issue":"2","key":"398_CR4","first-page":"1","volume":"3","author":"W Knauf","year":"2015","unstructured":"Knauf W, Re D. Chronic lymphocytic leukemia: raising expectations in the treatment of elderly patients. J Leuk. 2015;3(2):1\u20138.","journal-title":"J Leuk."},{"issue":"18","key":"398_CR5","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","volume":"23","author":"MJ Keating","year":"2005","unstructured":"Keating MJ, O\u2019Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079\u201388.","journal-title":"J Clin Oncol"},{"issue":"4","key":"398_CR6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, O\u2019Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975\u201380.","journal-title":"Blood"},{"issue":"4","key":"398_CR7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2008.17.2619","volume":"27","author":"KA Foon","year":"2009","unstructured":"Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27(4):498\u2013503.","journal-title":"J Clin Oncol"},{"issue":"9980","key":"398_CR8","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","volume":"385","author":"P Hillmen","year":"2015","unstructured":"Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873\u201383.","journal-title":"Lancet"},{"key":"398_CR9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3324\/haematol.2012.068791","volume":"98","author":"E Nikitin","year":"2013","unstructured":"Nikitin E, Kisilichina D, Zakharov O, et al. Randomised comparison of FCR-Lite and ClR (chlorambucil plus rituximab) regimens in elderly patients with chronic lymphocytic leukemia. Haematologica. 2013;98:473 (abstract S1147).","journal-title":"Haematologica."},{"key":"398_CR10","unstructured":"Michallet AS, Aktan M, Schuh A, et al. Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukaemia: primary results from the randomised phase IIIb MABLE study. XVI International Workshop on Chronic Lymphocytic Leukaemia. Sydney, Australia, 6\u20139 Sept, 2015."},{"issue":"7","key":"398_CR11","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","volume":"29","author":"V Goede","year":"2015","unstructured":"Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29(7):1602\u20134.","journal-title":"Leukemia"},{"issue":"20","key":"398_CR12","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105\u201324.","journal-title":"Stat Med"},{"issue":"3","key":"398_CR13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","volume":"17","author":"G Salanti","year":"2008","unstructured":"Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17(3):279\u2013301.","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"398_CR14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jval.2015.12.018","volume":"19","author":"U Becker","year":"2016","unstructured":"Becker U, Briggs AH, Moreno SG, Ray JA, Ngo P, Samanta K. Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia unsuitable for full dose fludarabine based therapy. Value Health. 2016;19(4):374\u201382.","journal-title":"Value Health."},{"key":"398_CR15","doi-asserted-by":"crossref","first-page":"f6008","DOI":"10.1136\/bmj.f6008","volume":"347","author":"HY Wu","year":"2013","unstructured":"Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ. 2013;347:f6008.","journal-title":"BMJ"},{"issue":"2","key":"398_CR16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ctrv.2014.11.004","volume":"41","author":"P Ladyzynski","year":"2015","unstructured":"Ladyzynski P, Molik M, Foltynski P. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia. Cancer Treat Rev. 2015;41(2):77\u201393.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"398_CR17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","volume":"37","author":"MJ Lipinski","year":"2016","unstructured":"Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J. 2016;37(6):536\u201345.","journal-title":"Eur Heart J"},{"issue":"2","key":"398_CR18","doi-asserted-by":"crossref","first-page":"djv318","DOI":"10.1093\/jnci\/djv318","volume":"108","author":"S Mocellin","year":"2015","unstructured":"Mocellin S, Pilati P, Briarava M, Nitti D. Breast cancer chemoprevention: a network meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2015;108(2):djv318.","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"398_CR19","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00277-015-2310-6","volume":"94","author":"A Messori","year":"2015","unstructured":"Messori A, Fadda V, Maratea D, Trippoli S. First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis. Ann Hematol. 2015;94(6):1003\u20139.","journal-title":"Ann Hematol"},{"issue":"5","key":"398_CR20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, et al. Renin-Angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728\u201341.","journal-title":"Am J Kidney Dis"},{"key":"398_CR21","volume-title":"Modelling survival data in medical research","author":"D Collett","year":"2003","unstructured":"Collett D. Modelling survival data in medical research. London: Chapman & Hall\/CRC; 2003."},{"issue":"24","key":"398_CR22","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815\u201334.","journal-title":"Stat Med."},{"key":"398_CR23","unstructured":"Dias S, Welton, NJ, Sutton AJ, Ades A. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2014. http:\/\/www.nicedsu.org.uk\/evidence-synthesis-tsd-series(2391675).htm . Last accessed April 2016."},{"key":"398_CR24","doi-asserted-by":"crossref","DOI":"10.1201\/b16018","volume-title":"Bayesian Data Analysis","author":"A Gelman","year":"2013","unstructured":"Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian Data Analysis. 3rd ed. Aylesbury: Taylor & Francis; 2013.","edition":"3"},{"key":"398_CR25","unstructured":"Plummer M. JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling. DSC 2003 Working Papers (Draft versions). 2003. https:\/\/www.r-project.org\/conferences\/DSC-2003\/Drafts\/Plummer.pdf . Last accessed January, 2016."},{"key":"398_CR26","volume-title":"Bayesian approaches to clinical trials and health-care evaluation","author":"DJ Spiegelhalter","year":"2004","unstructured":"Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Cambridge: Wiley; 2004."},{"issue":"12","key":"398_CR27","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med"},{"issue":"16","key":"398_CR28","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","volume":"114","author":"BF Eichhorst","year":"2009","unstructured":"Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114(16):3382\u201391.","journal-title":"Blood"},{"issue":"1","key":"398_CR29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12000","volume":"159","author":"WU Knauf","year":"2012","unstructured":"Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol. 2012;159(1):67\u201377.","journal-title":"Br J Haematol"},{"issue":"35","key":"398_CR30","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","volume":"25","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25(35):5616\u201323.","journal-title":"J Clin Oncol"},{"issue":"24","key":"398_CR31","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","volume":"343","author":"KR Rai","year":"2000","unstructured":"Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750\u20137.","journal-title":"N Engl J Med"},{"key":"398_CR32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V126.23.1733.1733","volume":"126","author":"V Goede","year":"2015","unstructured":"Goede V, Fischer K, Bosch F, et al. Updated survival analysis from the CLL11 study: obinutuzumab versus rituximab in chemoimmunotherapy-treated patients with chronic lymphocytic leukemia. Blood. 2015;126:23 (abstract 1733).","journal-title":"Blood."},{"key":"398_CR33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","volume":"1","author":"M Buyse","year":"2000","unstructured":"Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1:49\u201367.","journal-title":"Biostatistics."},{"issue":"6","key":"398_CR34","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2014.963077","volume":"56","author":"V Goede","year":"2015","unstructured":"Goede V, Eichhorst B, Fischer K, Wendtner CM, Hallek M. Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(6):1585\u201392.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"398_CR35","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3109\/10428194.2015.1085528","volume":"57","author":"S Lepretre","year":"2016","unstructured":"Lepretre S, Dartigeas C, Feugier P, Marty M, Salles G. Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies. Leuk Lymphoma. 2016;57(4):852\u201365.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"398_CR36","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ctrv.2012.02.006","volume":"38","author":"MM Cheng","year":"2012","unstructured":"Cheng MM, Goulart B, Veenstra DL, Blough DK, Devine EB. A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia. Cancer Treat Rev. 2012;38(8):1004\u201311.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"398_CR37","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ctrv.2012.05.007","volume":"39","author":"T Terasawa","year":"2013","unstructured":"Terasawa T, Trikalinos NA, Djulbegovic B, Trikalinos TA. Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis. Cancer Treat Rev. 2013;39(4):340\u20139.","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"398_CR38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V126.23.493.493","volume":"126","author":"S Stilgenbauer","year":"2015","unstructured":"Stilgenbauer S, Ilhan O, Woszczyk D, et al. Safety and efficacy of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia: subgroup analysis of the green study. Blood. 2015;126(23):493.","journal-title":"Blood"},{"issue":"5","key":"398_CR39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cpt.85","volume":"97","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhang LL, Champlin RE, Wang ML. Targeting Bruton\u2019s tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther. 2015;97(5):455\u201368.","journal-title":"Clin Pharmacol Ther"},{"issue":"25","key":"398_CR40","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337.","journal-title":"N Engl J Med"},{"key":"398_CR41","doi-asserted-by":"crossref","unstructured":"Von Tresckow J, Cramer P, Bahlo J, et al. CLL2-BIG\u2014a novel treatment regimen of bendamustine followed by GA101 and ibrutinib followed by ibrutinib and GA101 maintenance in patients with chronic lymphocytic leukemia (CLL): interim results of a phase II-trial. 57th American Society of Hematology Annual Meeting. Orlando, FL, USA, December 5\u20138, 2015 (abstract 4151).","DOI":"10.1182\/blood.V126.23.4151.4151"},{"key":"398_CR42","doi-asserted-by":"crossref","unstructured":"Hansen S, Enquist J, Iwig J, et al. PDK1 inhibitors SNS-229 and SNS-510 cause pathway modulation, apoptosis and tumor regression in hematologic cancer models in addition to solid tumors. Mol Cancer Ther. 2015;14(12 suppl 2) (abstract C198). In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics (November 5\u20139, 2015; Boston, MA. Philadelphia).","DOI":"10.1158\/1535-7163.TARG-15-C198"},{"issue":"25","key":"398_CR43","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","volume":"126","author":"SM O\u2019Brien","year":"2015","unstructured":"O\u2019Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia. Blood. 2015;126(25):2686\u201394.","journal-title":"Blood"},{"issue":"2","key":"398_CR44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","volume":"128","author":"BL Lampson","year":"2016","unstructured":"Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128(2):195\u2013203.","journal-title":"Blood"},{"key":"398_CR45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1748-5908-7-61","volume":"7","author":"S Woolf","year":"2012","unstructured":"Woolf S, Sch\u00fcnemann HJ, Eccles MP, Grimshaw JM, Shekelle P. Developing clinical practice guidelines: types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendations. Implement Sci. 2012;7:61.","journal-title":"Implement Sci."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0398-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T06:47:33Z","timestamp":1601016453000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0398-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,17]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0398-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,17]]}}}